



## 2024 – A Year in Review

As we transition to a new year, this is time to reflect upon the year gone by and evaluate the status of the Indian Journal of Nephrology (IJN), the official publication of the Indian Society of Nephrology, in its quest to serve as a vital platform for disseminating high-quality research in nephrology relevant to the kidney health community in India and around the world.

A notable development in 2024 was the change in IJN's publishing partnership from Wolters Kluwer Medknow to Scientific Scholar.<sup>1</sup> This shift is aimed at enhancing accessibility and streamlining the editorial process, leading to improved user experience and ensuring continued excellence in publishing peer-reviewed research.

The journal maintained its bi-monthly publication schedule, featuring a diverse array of articles that addressed pressing issues in nephrology.

The journal published several high-impact reviews authored by global experts in the field, commissioned by the journal's editorial board. These covered practical topics of contemporary interest such as Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,<sup>2</sup> IgA nephropathy: both disease mechanisms<sup>3</sup> and advances in therapy,<sup>4</sup> membranous nephropathy,<sup>5</sup> diagnostic utility of urine microscopy<sup>6</sup> and therapies for arteriovenous fistula and graft dysfunction.<sup>7</sup>

We published a series of articles discussing issues related to kidney transplantation, ranging from ethical issues pertaining to the role of transplant professionals in transplant commercialism in India,<sup>8</sup> the growing experience of ABO-incompatible transplants,<sup>9</sup> the use of induction immunosuppression in low-risk living donor transplants,<sup>10</sup> the understanding of asymptomatic bacteriuria in kidney transplant recipients,<sup>11</sup> and the promise held by emerging therapeutic approaches such as imlifidase.<sup>12</sup>

Articles addressing pediatric nephrology emphasized innovations in critical care and diagnostics, reflecting a growing focus on improving outcomes for children with kidney diseases. Notable ones included a variety of issues relating to management of children with difficult-to-treat nephrotic syndrome<sup>13-15</sup> and publication of guidelines for the treatment of children with urinary tract infection and vesicoureteric reflux.<sup>16</sup>

Issues of practical importance were highlighted, such as the role of desmopressin acetate before kidney biopsy in reducing bleeding risk in patients with kidney dysfunction,<sup>17</sup> checking the adequacy of kidney biopsy samples with a smartphone camera,<sup>18</sup> and glomerular diameter measurements for patients with IgA nephropathy.<sup>19</sup>

Chronic Kidney Disease of Unknown Etiology and its possible link with environmental factors are emerging as a significant public health problem in India - as shown in reports from Chhattisgarh<sup>20</sup> and Odisha<sup>21</sup> - highlighting the need for more research and advocacy on this topic.

The Journal is committed to welcoming submissions from allied healthcare professionals, as reflected in articles by renal nurses, specifically relating to an audit of assisting kidney biopsy procedures<sup>22</sup> and the effectiveness of yoga and meditation on quality of life among hemodialysis patients.<sup>23</sup>

The journal continued its tradition of publishing unique case reports, such as kidney disease associated with filaria,<sup>24,25</sup> highlighting parasitic infections' impact on kidney health.

With an impact factor of 0.8 as reported by Clarivate Analytics and a Scopus CiteScore of 1.4, IJN continued to hold its position as a reputable journal indexed in major databases such as PubMed Central, SCOPUS, and Web of Science. Its open-access model ensured that cutting-edge research reached a wide audience, including clinicians, researchers, and policymakers.

As IJN moves into 2025, it is well-positioned to build on its legacy of excellence. The journal's emphasis on regional challenges, ethical issues, and innovative therapies ensures its relevance in addressing both local and global nephrology concerns.

In summary, the IJN continued its journey of progress in 2024. Through its diverse publications, IJN not only advanced scientific knowledge but also fostered critical conversations about improving kidney care delivery across India and beyond. We look forward to receiving high-quality submissions to the journal to fulfill the mission of its parent society.

In addition to the contributors, special thanks are due to all the editors and reviewers for their contributions to elevating the quality of the work published in the journal. You make time to do this voluntary work for the journal and we are grateful.

We welcome feedback – both laudatory and critical, as we believe it is only in this environment of open dialogue, discussion, and argumentation for which Indian institutions have been well-known since ancient times. I look forward to an even more exciting and fruitful 2025 for the journal.

### Conflicts of interest

There are no conflicts of interest.

**Vivekanand Jha<sup>1</sup>**

<sup>1</sup>Department of Nephrology, George Institute for Global Health, Jasola, New Delhi, Delhi, India

**Corresponding author:** Vivekanand Jha, Department of Nephrology, George Institute for Global Health, Jasola, New Delhi, Delhi, India.  
E-mail: vjha@georgeinstitute.org.in

**References**

- Duttgupta S. The journey of indian journal of nephrology. *Indian J Nephrol* 2024;34:4-5.
- Roper T, Salama AD. ANCA-associated vasculitis: Practical issues in management. *Indian J Nephrol* 2024;34:6-23.
- Roberts LE, Williams CEC, Oni L, Barratt J, Selvaskandan H. IgA nephropathy: emerging mechanisms of disease. *Indian J Nephrol* 2024;34:297-309.
- Mathur M, Sahay M, Pereira BJG, Rizk DV. State-of-art therapeutics in IgA nephropathy. *Indian J Nephrol* 2024;34:417-30.
- Efe O, So PNH, Anandh U, Lerma EV, Wiegley N. An updated review of membranous nephropathy. *Indian J Nephrol* 2024;34:105-18.
- Gaggar P, Raju SB. Diagnostic utility of urine microscopy in kidney diseases. *Indian J Nephrol* 2024;34:213-21.
- Vachharajani TJ, Bhargava V, Sequeira A, Meena P. Existing and evolving therapies for arteriovenous fistula and graft dysfunction. *Indian J Nephrol* 2024;34:552-60.
- Nagral S. Transplant professionals and transplant commercialism in India: The Difficulty of Being Good. *Indian J Nephrol* 2024;34:549-51.
- Pawar N, Tiwari V, Gupta A, Divyaveer S, Rather I, Chadha S, Bhargava V, Malik M, Gupta A, Bhalla AK, Rana DS, Gupta P. ABO-incompatible renal transplant: A single-center experience from India. *Indian J Nephrol* 2024;34:24-30.
- Jha PK, Bansal SB, Sharma R, Sethi SK, Bansal D, Nandwani A, Kher A, Yadav DK, Gadde A, Mahapatra AK, Rana AS, Sodhi P, Jain M, Kher V. Role of induction in a haplomatch, related, low-risk, living-donor kidney transplantation with triple drug immunosuppression: A single-center study. *Indian J Nephrol* 2024;34:246-51.
- Mani SSR, Thomas A, Alam R, Lalwani M, Valson AT, Yadav B, Eapen JJ, John EE, Yusuf S, Mukha RP, Rajadoss MKP, Mercy D, Alexander S, Varughese S, David VG. Profile, risk factors, and outcomes of asymptomatic bacteriuria in kidney transplant recipients with normal pretransplant genitourinary tract: A single-center experience. *Indian J Nephrol* 2024;34:37-44.
- Krishnan N, Briggs D. Imlifidase: Is it the magic wand in renal transplantation? *Indian J Nephrol* 2024;34:291-6.
- Gaur S, Paul PP, Motamarri M. Rituximab/Mycophenolate combination therapy in children with calcineurin inhibitor-resistant FSGS. *Indian J Nephrol* 2024;34:45-9.
- Yadav D, Mantan M, Mahajan B. Comparison of urinary beta-2 microglobulin levels in children with SSNS and calcineurin inhibitor-treated SRNS. *Indian J Nephrol* 2024;34:149-54.
- Deepthi RV, Arumadi M, Eriyat V, Mathew SK, Mathew BS, Agarwal I, Prabha R. Exposure to Mycophenolic acid and its clinical response in an indian pediatric population with nephrotic syndrome. *Indian J Nephrol* 2024;34:323-7.
- Meena J, Bagga A, Hari P. Management of Urinary Tract Infections and Vesicoureteric Reflux: Key Updates from revised indian society of pediatric nephrology guidelines 2023. *Indian J Nephrol* 2024;34:442-7.
- Sethi J, Bansal S, Lal A, Kohli HS, Rathi M. Role of Desmopressin acetate before percutaneous ultrasound-guided kidney biopsy in patients with kidney dysfunction. *Indian J Nephrol* 2024;34:228-32.
- Modi SS, Ramamurthy S, Balasubramanian S, Kumar S, Daruwala F. Bedside method to check the adequacy of kidney biopsy sample with a smartphone camera and macro lenses: a prospective cohort study. *Indian J Nephrol* 2024;34:233-6.
- Manocha A, Fathima N, Gowrishankar S. Glomerular diameter measurements on light microscopy: A new parameter available to pathologists and its utility in IgA nephropathy. *Indian J Nephrol* 2024;34:344-9.
- Galhotra A, Rathore V, Pal R, Nayak S, Ramasamy S, Patel S, Joshi P, Nagarkar NM, Jha V. Clinico-epidemiological profile of patients with chronic kidney diseases of unknown etiology: A hospital-based, cross-sectional study from central india. *Indian J Nephrol* 2024;34:241-5.
- Biswas P, Sahu AK, Nath SR, Mir SA, Naik PK, Kariali E, Nayak B, Shristi S, Nayak SK, Baitharu I. Prevalence of chronic kidney disease and its association with pesticide exposure in Bargarh district, Odisha, India. *Indian J Nephrol* 2024;34:467-74.
- Thakur M, Mawar S, Murry LL, Sharma DK. Clinical audit of assisting renal biopsy procedure performed in nephrology unit of a tertiary care hospital with a view to develop standard nursing procedure protocol. *Indian J Nephrol* 2024;34:328-31.
- Parekh AJ, Prakasam A. Effectiveness of yoga and meditation on quality of life among patients undergoing hemodialysis. *Indian J Nephrol* 2024;34:533-6.
- Badge R, Rathore V, Aggarwal J. Filariasis-associated secondary membranous nephropathy: A rare presentation. *Indian J Nephrol* 2024;34:385-7.
- Prasad P, Gupta N, Verma R, Prasad N, Kaul A, Agrawal V, Jain M. Caught by surprise - microfilaria in renal biopsies. *Indian J Nephrol* 2024;34:257-60.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**How to cite this article:** Jha V. 2024 – A Year in Review. *Indian J Nephrol*. 2025;35:1-2. doi: 10.25259/IJN\_821\_2024

**Received:** 30-12-2024; **Accepted:** 30-12-2024;  
**Published:** 04-01-2025

**DOI:** 10.25259/IJN\_821\_2024

